Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxymetazoline for Acquired Blepharoptosis Due to Periocular Synkinesis
NCT05945615Phase 3Completed
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Mucinex Full Force Nasal Spray in blepharoptosis, Synkinesis, sponsored by Penn State Health Milton S. Hershey Medical Center. Started Jan 2024; status: completed.
02
Drugs
Mucinex Full Force Nasal Spray
03
Conditions
blepharoptosisSynkinesis
Beyond the preview
Go deeper on NCT05945615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05945615.